Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 4/20 | 0.40 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.40 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660621 | 0.84 | DYRK1A (0.36) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL5406375 | 0.84 | HDAC3 (0.37) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL5387429 | 0.81 | PTGS1 (0.45) | SLC16A3SLC16A1MCTS1GRM5GRM3 | |
| SCHEMBL5382364 | 0.81 | GRM5 (0.39) | SLC16A3SLC16A1MCTS1GRM5 | |
| SCHEMBL14415512 | 0.80 | GRM5 (0.40) | GRM5GRM3 | |
| SCHEMBL5396403 | 0.77 | SLC16A3 (0.37) | SLC16A3SLC16A1MCTS1GRM5GRM3 | |
| SCHEMBL1661510 | 0.75 | DYRK1A (0.40) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL1659820 | 0.75 | GPR55 (0.34) | — | |
| SCHEMBL14727667 | 0.73 | LRRK2 (0.36) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL5406662 | 0.73 | GPR52 (0.46) | SLC16A3SLC16A1MCTS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20060264474-A1 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2006-11-23 | — | — | US | disclosed |
| WO-2004089911-A1 | PYRAZOLE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS USEFUL IN THE TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264474-A1 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | SLC16A3 4845/4885SLC16A1 4830/4885MCTS1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.